Tyler Durns

Huntsman Mental Health Institute (B.R.L., K.B., T.D.), University of Utah, Salt Lake City, Utah, USA.

2 papers in the library · 60 citations · publishing 2023-2026

Papers

HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer.

Journal of pain and symptom management September 1, 2023 Benjamin R Lewis, Eric L Garland, Kevin Byrne et al. 60 citations

Psilocybin-assisted group therapy appears safe and feasible for treating depression in cancer patients. In an open-label pilot trial, twelve participants with a depressive disorder received one high-dose (25 mg) psilocybin session within a three-week group program. Depression scores on the HAM-D scale decreased substantially from an average of 21.5 at baseline to 10.09 at two weeks and 14.83 at six months. Six of twelve participants met remission criteria (HAM-D below 7) at two weeks, and no serious adverse events occurred. The group format may reduce therapist time while maintaining possible efficacy, warranting further study.

DOI: 10.1016/j.jpainsymman.2023.06.006 Full text Psychedelic-assisted therapy Palliative care Psilocybin-assisted therapy Cancer treatment +3

Contextualizing Violence Risk Associated With Hallucinogens

FOCUS The Journal of Lifelong Learning in Psychiatry January 1, 2026 Tyler Durns, Greg Iannuzzi

Psilocybin, LSD, and MDMA have regained attention for their potential psychiatric benefits, but their effects on aggression and violence are not well understood. This review examines the historical, medical, legal, and cultural contexts of these compounds, along with how substance type, dose, set and setting, psychiatric comorbidity, and environmental factors influence violence risk. It discusses prevention and response strategies such as harm reduction, risk assessment, and treatment. The article concludes that individual risk factors mediating violence for users of these substances require further research.

DOI: 10.1176/appi.focus.20250027 Lysergic acid diethylamide MDMA Psilocybin Hallucinogen +10